Combined Anterior Suprascapular Nerve Block and Superficial Cervical Plexus Block In Shoulder Arthroplasty Surgery

Diaphragmatic Paralysis Clinical Trial

Official title:

Application Of Combined Anterior Suprascapular Nerve Block and Superficial Cervical Plexus Block In Reverse Shoulder Arthroplasty Surgery, A Case Series

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06146179
• Other study ID #: 2023/0363
• Status: Active, not recruiting
• Start date: November 1, 2023
• Est. completion date: May 30, 2024

Study information

• Verified date: March 2024
• Source: Istanbul Medeniyet University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The suprascapular nerve, originating from the C5 trunk, provides innervation to the acromioclavicular and glenohumeral joints. The supraclavicular nerve, a branch of the cervical plexus, contributes to the sensory innervation of the upper deltoid region. Cervical and brachial plexus blocks can cause diaphragm paralysis. This study examined the effects of low-volume combined anterior suprascapular nerve block and superficial cervical plexus block on pain and phrenic nerve in participants underwent reverse shoulder arthroplasty surgery.

Description:

A retrospective analysis was performed on data obtained from eight participants who underwent reverse shoulder arthroplasty surgery. Anterior suprascapular nerve block and superficial cervical plexus block were applied to these participants. Anterior suprascapular nerve block was performed using 5 ml and superficial cervical plexus block was performed using 3 ml of %0,5 bupivacaine. Ultrasound was used to measure the diaphragm thickness at the end of inspiration and expiration, and to calculate the diaphragm thickness fraction. Postoperative pain management included patient-controlled analgesia with morphine, opioid consumption and VAS score recorded by pain observation forms.

Data will be collected by examining these pain observation forms and diaphragm thickness measurements.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 8
• Est. completion date: May 30, 2024
• Est. primary completion date: March 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Population is defined by database within a given time frame

• Participants who underwent combined anterior suprascapular nerve block and superficial cervical plexus block in reverse shoulder arthroplasty surgery

• Participants aged 18-80

• ASA I-II-III

Exclusion Criteria:

• ASA score > III

• Pediatric individuals under 18 years of age

• Individuals who are pregnant

• Known diaphragmatic paralysis

• Had an allergy or toxicity to local anesthetic agents

• Have an opioid drug allergy

Related Conditions & MeSH terms

• Anterior Suprascapular Nerve Block
• Diaphragmatic Paralysis
• Paralysis
• Phrenic Nerve Paralysis
• Respiratory Paralysis
• Superficial Cervical Plexus Block

Locations

Country	Name	City	State
Turkey	Istanbul Medeniyet University	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul Medeniyet University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Patient Satisfaction with 5 point Likert Patient Satisfaction scale at postoperatively 24th. Hours	Postoperative 24th. hour 5 point Likert Patient Satisfaction scale (1-Very dissatisfied, 2 - Dissatisfied, 3 - Unsure, 4 - Satisfied, 5 - Very satisfied)	Postoperatively 24th hour
Other	Postoperative Nausea and Vomiting	Postoperative Nausea and Vomiting Score ( PONV0: No Nausea, No vomiting; PONV1: Nausea present, No vomiting; PONV2: Nausea and vomiting present; PONV3: Vomiting>2 epizodes in 30th. min; PONV4:Vomiting>3 epizodes in 30th.min)	During Postoperatively 24 hour
Primary	Postoperative Change Ratio of Diaphragm Thickness Fraction	Postoperative Change Ratio of Diaphragm Thickness Fraction (%) at Postoperatively 30th. min.	Postoperatively 30th. min.
Secondary	Pain Assessment with Visual Analogue Scale at postoperatively 30th. Min.	Postoperative VAS score (Ranging from 0-10)	Postoperatively 30th. min
Secondary	Pain Assessment with Visual Analogue Scale at postoperatively 4th. Hours.	Postoperative VAS score (Ranging from 0-10)	Postoperatively 4th. hour
Secondary	Pain Assessment with Visual Analogue Scale at postoperatively 6th. Hours.	Postoperative VAS score (Ranging from 0-10)	Postoperatively 6th. hour
Secondary	Pain Assessment with Visual Analogue Scale at postoperatively 12th. Hours.	Postoperative VAS score (Ranging from 0-10)	Postoperatively 12th. hour
Secondary	Pain Assessment with Visual Analogue Scale at postoperatively 24th. Hours.	Postoperative VAS score (Ranging from 0-10)	Postoperatively 24th. hour
Secondary	Opioid Consumption at postoperatively 30th. Min.	Postoperative Opioid Consumption with Morphine PCA (0.5 mg/cc, demand dose 2 cc, lock of time; 10 min. )	Postoperatively 30th. min.
Secondary	Opioid Consumption at postoperatively 4th. Hours.	Postoperative Opioid Consumption with Morphine PCA (0.5 mg/cc, demand dose 2 cc, lock of time; 10 min. )	Postoperatively 4th. hour
Secondary	Opioid Consumption at postoperatively 6th. Hours.	Postoperative Opioid Consumption with Morphine PCA (0.5 mg/cc, demand dose 2 cc, lock of time; 10 min. )	Postoperatively 6th. hour
Secondary	Opioid Consumption at postoperatively 12th. Hours.	Postoperative Opioid Consumption with Morphine PCA (0.5 mg/cc, demand dose 2 cc, lock of time; 10 min. )	Postoperatively 12th. hour
Secondary	Opioid Consumption at postoperatively 24th. Hours.	Postoperative Opioid Consumption with Morphine PCA (0.5 mg/cc, demand dose 2 cc, lock of time; 10 min. )	Postoperatively 24th. hour